Toth PP - Search Results

1

Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.

Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Toth PP, et al. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. Circulation. 2017. PMID: 28249876 Free article.

2

Drug safety evaluation of rosuvastatin.

Toth PP, Dayspring TD. Toth PP, et al. Expert Opin Drug Saf. 2011 Nov;10(6):969-86. doi: 10.1517/14740338.2012.626764. Expert Opin Drug Saf. 2011. PMID: 21999163 Review.

3

Is HPS2-THRIVE the death knell for niacin?

Toth PP, Murthy AM, Sidhu MS, Boden WE. Toth PP, et al. J Clin Lipidol. 2015 May-Jun;9(3):343-50. doi: 10.1016/j.jacl.2015.01.008. Epub 2015 Jan 30. J Clin Lipidol. 2015. PMID: 26073392 Review.

4

Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database of Lipids Study (VLDL-2B).

Elshazly MB, Quispe R, Michos ED, Sniderman AD, Toth PP, Banach M, Kulkarni KR, Coresh J, Blumenthal RS, Jones SR, Martin SS. Elshazly MB, et al. Among authors: toth pp. Circulation. 2015 Aug 25;132(8):667-76. doi: 10.1161/CIRCULATIONAHA.115.016163. Epub 2015 Jul 2. Circulation. 2015. PMID: 26137953 Free PMC article. Clinical Trial.

5

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.

Blom DJ, Dent R, Castro RC, Toth PP. Blom DJ, et al. Among authors: toth pp. Vasc Health Risk Manag. 2016 May 9;12:185-97. doi: 10.2147/VHRM.S102564. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27274264 Free PMC article. Review.

6

PCSK9 and Lipoprotein(a): The Plot Thickens.

Toth PP. Toth PP. Circ Res. 2016 Jun 24;119(1):3-6. doi: 10.1161/CIRCRESAHA.116.309011. Circ Res. 2016. PMID: 27340263 No abstract available.

7

Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction.

Toth PP. Toth PP. Am J Cardiol. 2016 Sep 15;118(6 Suppl):19A-32A. doi: 10.1016/j.amjcard.2016.05.028. Am J Cardiol. 2016. PMID: 27620356 Review.

8

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.

Banach M, Stulc T, Dent R, Toth PP. Banach M, et al. Among authors: toth pp. Int J Cardiol. 2016 Dec 15;225:184-196. doi: 10.1016/j.ijcard.2016.09.075. Epub 2016 Sep 26. Int J Cardiol. 2016. PMID: 27728862 Review.

9

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.

Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D. Sattar N, et al. Among authors: toth pp. Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31. Am J Cardiol. 2017. PMID: 28844508 Free article. Clinical Trial.

10

Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.

Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP. Bays HE, et al. Among authors: toth pp. J Am Heart Assoc. 2017 Aug 8;6(8):e005639. doi: 10.1161/JAHA.117.005639. J Am Heart Assoc. 2017. PMID: 28862926 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

433 results

Search Page